Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: A10AB04;A10AD04

Humalog(insulin lispro)

Diabetes Mellitus

Marketing Authorisation Holder: Eli Lilly Nederland B.V.

EMA Authorisation: 30/04/1996

INN: insulin lispro

Indication

For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Humalog — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.